Brentuximab Vedotin First Treatment Option for Relapsed Hodgkin Lymphoma and...
Brentuximab Vedotin First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma)SummaryThe group of cancers that originate in the lymphatic...
View ArticleHodgkin Lymphoma Pipeline Review, H2 2012
Hodgkin Lymphoma Pipeline Review, H2 2012SummaryGlobal Markets Directs, ‘Hodgkin Lymphoma – Pipeline Review, H2 2012′, provides an overview of the Hodgkin Lymphoma therapeutic pipeline. This report...
View ArticleClik here to view.
Hodgkin Lymphoma Global Clinical Trials Review, Q4, 2010
Price: $ 1000 (Single User License) GlobalData’s clinical trial report, “ Hodgkin Lymphoma Global Clinical Trials Review, Q4, 2010″” provides data on the Hodgkin Lymphoma clinical trial scenario....
View ArticleClik here to view.
Non- Hodgkin Lymphoma – Pipeline Review, H2 2012
Price: $ 2500 (Single User License) Non-Hodgkin Lymphoma Pipeline Review, H2 2012 Global Markets Directs, ‘Non-Hodgkin Lymphoma Pipeline Review, H2 2012′, provides an overview of the Non-Hodgkin...
View ArticleClik here to view.
B- Cell Non- Hodgkin Lymphoma – Pipeline Review, H2 2012
Price: $ 2500 (Single User License) B-Cell Non-Hodgkin Lymphoma – Pipeline Review, H2 2012SummaryGlobal Markets Directs, ‘B-Cell Non-Hodgkin Lymphoma – Pipeline Review, Global Markets Directs,...
View Article
